Citations

Clear

2303 citation(s) found for "Yu, Edward".

Prevalence and Epidemiology of Pulmonary Hypertension Amongst Patients With Sarcoidosis
Shah, J.R., Kulkarni, Mithun V. , Lewin, E., Mohan, Balwinder, Singh, Shraddha , Sharma, Vishal , Trivedi, Rishika , Malik, Asad , Ibrahim, M., Tan, Hiang Keat , Anosh, M., Patel, Pooja , Yusuf, A., Kavarthapu, Anusha, Kulkarni, M., Gupta, Abhishek , Malik, A., Patel, Urvish

Mayo Clinic

B40. POTPOURRI IN ILD: SPANNING THE SPECTRUM FROM RARE TO COMMON LUNG DISEASES | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A3289-A3289

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3289 Get It

Memory Performance in Asymptomatic and Prodromal Familial Frontotemporal Lobar Degeneration: Findings from the ALLFTD Consortium (P13-6.001)
Boeve, Bradley, Fields, Julie A. , Syrjanen, Jeremy, Kremers, Walter K. , Staffaroni, Adam M. , Huey, Edward D. , Rascovsky, Katya, Ramos, Marisa, Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard, Kremers, Walter K

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203737 Get It

Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results
Bhojani, Naeem , Bidair, Mo, Kramolowsky, Eugene V., Desai, Mihir, Doumanian, Leo, Zorn, Kevin C. , Elterman, Dean , Kaufman, Ronald P., Eure, Gregg , Badlani, Gopal , Plante, Mark , Uchio, Edward , Gin, Greg , Paterson, Ryan, So, Alan , Roehrborn, Claus, Motola, Jay , Kaplan, Steven, Humphreys, Mitch, Bidair, Mohamed

Mayo Clinic

Journal of Urology | April 28, 2023 | Volume: 210 | Issue: 1 | Pages: 143-153

10.1097/ju.0000000000003483 | PMID 37115632 Get It

Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder
Dickerson, David , Mariano, Edward R. , Szokol, Joseph W., Harned, Michael , Clark, Randall M, Mueller, Jeffrey T. , Shilling, Ashley , Udoji, Mercy A. , Mukkamala, S Bobby, Doan, Lisa , Wyatt, Karla , Elkassabany, Nabil , Beck, Stacy , Wiechmann, Lisa, Chiao, Franklin, Halle, Steven G, Krishnan, Deepak G. , Cramer, John D. , Esa, Wael Ali Sakr, Muse, Iyabo O. , Baratta, Jaime L., Rosenquist, Richard W. , Gulur, Padma, Shah, Shalini , Kohan, Lynn , Robles, Jennifer, Yang, Stephen C. , Hadeed, Josef G., Schwartz, Gary , Sprintz, Michael, Urish, Kenneth L. , Walton, Ashley , Keith, Lauren, Buvanendran, Asokumar , Dickerson, David M , Muse, Iyabo O , Rosenquist, Richard , Schwenk, Eric S , Schwartz, Gary , Mariano, Edward R , Clark, Randall M., Schwalb, Jason M. , Eloy, Jean Daniel , Schwenk, Eric S. , Allen, Brian F.S. , Englesbe, Michael J. , Walton, Ashley, Keith, Lauren

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 25, 2023 | Volume: 49 | Issue: 10 | Pages: 716-724

10.1136/rapm-2023-104435 | PMID 37185214 Get It

Significant knowledge gaps exist in the perioperative pain management of patients with a history of chronic pain, substance use disorder, and/or opioid tolerance as highlighted in the US Health and Human Services Pain Management Best Practices Inter-Agency Task Force 2019 report. The report emphasized the challenges of caring for these populations and the need for multidisciplinary care and a comprehensive approach. Such care requires stakeholder alignment across multiple specialties and care settings. With the intention of codifying this alignment into a reliable and efficient processes, a consortium of 15 professional healthcare societies was convened in a year-long modified Delphi consensus process and summit. This process produced seven guiding principles for the perioperative care of patients with chronic pain, substance use disorder, and/or preoperative opioid tolerance. These principles provide a framework and direction for future improvement in the optimization and care of ‘complex’ patients as they undergo surgical procedures.
OA29 Flares following COVID-19 vaccination in patients with idiopathic inflammatory myopathies: combined analysis from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) studies
Gupta, Latika, Naveen, R, Griger, Zolten, Jagtap, Kshitij , Nikiphorou, Elena , Parodis, Ioannis , Kuwana, Masataka , Group, COVAD Study, Ordóñez, Andrea Bran , Parodis, Ioannis , Jagtap, Kshitij , Agarwal, Vishwesh , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Distler, Oliver , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Milchert, Marcin , Makol, Ashima , Pauling, John D , Wincup, Chris , Lilleker, James B , Nune, Arvind , Day, Jessica , Chinoy, Hector , Group, COVAD Study, Agarwal, Vikas , Aggarwal, Rohit

Mayo Clinic

Rheumatology | April 24, 2023 | Volume: 62 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kead104.029 Get It

Abstract Background/Aims Flares following COVID-19 vaccination are an emerging concern among patients with rare rheumatic disease like idiopathic inflammatory myositis (IIMs), whereas data and understanding of this is rather limited. We aimed to study the prevalence, characteristics and determinants of IIM flares following COVID-19 vaccination. Methods CoVAD (COVID-19 Vaccination In Autoimmune Diseases) surveys are global patient self-reported e-surveys from 109 countries conducted in 2021 and 2022. Flares of IIM were defined by 4 definitions; a. patient self-reported, b. physician and immunosuppression (IS) denoted, c. sign directed (new erythematous rash, or worsening myositis or arthritis), d. MCID worsening of PROMISPF10a score between the patients who had taken both surveys. Descriptive statistics and multivariate regression were used to describe the predictors of flare. Cox-regression analysis was used to differentiate flares by IIM subtypes. Results Among the 1,278 IIM patients, aged 63 (50-71) years, 276 (21.5%) were dermatomyositis, 237 (18.5%) IBM, 899 (70.3%) were female and most were Caucasian (80.8%). Flares of IIM were seen in 123/1278 (9.6%), 163/1278 (12.7%), 112/1278 (8.7%), and 16/96 (19.6%) by definitions a-d respectively with median time to flare being 71.5 (10.7-235) days. Muscle weakness (69.1%), and fatigue (56.9%) were the most common symptoms of flare. The predictors of self-reported flare were: inactive/disease in remission prior to first dose of vaccine (OR = 4.3, 95%CI=2.4-7.6), and anxiety disorder (OR = 2.2, 95%CI=1.1-4.7). Rituximab use (OR = 0.3, 95%CI=0.1-0.7) and IBM (OR = 0.3, 95%CI=0.1-0.7) were protective. Physician defined flares were seen more often in females, mixed ethnicity, and those with asthma, ILD, and anxiety disorder (OR ranging 1.6-7.0, all p < 0.05). Notably, overlap myositis (OM) had higher HR for flare compared to polymyositis (HR = 2.3, 95%CI=1.2-4.4, p = 0.010). Conclusion Nearly one in ten individuals with IIM develop flares after vaccination, more so among women, those with overlap myositis, and inactive disease prior to vaccination. Formal definition of flares in IIM is needed. Disclosure L. Gupta: None. N. R: None. Z. Griger: None. V. Agarwal: None. P. Sen: None. M. Joshi: None. S. Saha: None. K. Jagtap: None. O. Distler: Honoraria; Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. E. Nikiphorou: Honoraria; Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly. Grants/research support; Pfizer and Lilly. A. Tan: Honoraria; Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. S. Shinjo: None. N. Ziade: Honoraria; Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre. M. Milchert: None. I. Parodis: Honoraria; Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. M. Kuwana: None. A. Makol: None. J. Pauling: None. C. Wincup: None. J. Lilleker: Honoraria; Sanofi Genzyme, Roche, and Biogen. A. Nune: None. J. Day: Grants/research support; CSL Limited. H. Chinoy: Consultancies; Novartis, Eli Lilly, Orphazyme, Astra Zeneca. Honoraria; UCB, and Biogen. Grants/research support; Eli Lilly and UCB. V. Agarwal: None. R. Aggarwal: Consultancies; Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, and Roivant.
P065 Post COVID-19 Syndrome in patients with autoimmune rheumatic diseases: Results from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
Gupta, Latika, Naveen, R, Jagtap, Kshitij , Nikiphorou, Elena , Parodis, Ioannis , Kuwana, Masataka , Group, COVAD Study, Parodis, Ioannis , Jagtap, Kshitij , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Agarwal, Vishwesh , Distler, Oliver , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Milchert, Marcin , Makol, Ashima , Pauling, John D , Wincup, Chris , Lilleker, James B , Nune, Arvind , Day, Jessica , Chinoy, Hector , Group, COVAD Study, Agarwal, Vikas , Aggarwal, Rohit

Mayo Clinic

Rheumatology | April 24, 2023 | Volume: 62 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kead104.106 Get It

Abstract Background/Aims Post COVID-19 syndrome (PCS) is an emerging cause of morbidity and poor quality of life in COVID-19 survivors. We aimed to assess the prevalence, risk factors, outcomes, and association with disease flares of PCS in patients with autoimmune rheumatic diseases (AIRDs) and non-rheumatic autoimmune diseases (nrAIDs), both vulnerable groups understudied in the current literature using data from the 2nd COVID-19 Vaccination in Autoimmune Diseases (COVAD) global multicentre patient self-reported e-survey. Methods The survey was circulated from February to July 2022 by the international COVAD Study Group (157 collaborators from 106 countries), and demographics, comorbidities, AIRD/nrAID status, COVID-19 history, vaccination details, and PROMIS physical and mental function were recorded. PCS was defined as symptom resolution time >90 days following acute COVID-19. Predictors of PCS were analysed using regression models for the different groups. Results 7666 total respondents completed the survey. Of these, 2650 respondents with complete responses had positive COVID-19 infection, and 1677 (45.0% AIRDs, 12.5% nrAIDs, 42.5% HCs) completed the survey >90 days post acute COVID-19. Of these, 136 (8.1%) had PCS. Prevalence of PCS was higher in AIRDs (10.8%) than healthy controls HCs (5.3%) (OR: 2.1; 95%CI: 1.4-3.1, p = 0.002). Across the entire cohort, a higher risk of PCS was seen in women (OR: 2.9; 95%CI: 1.1-7.7, p = 0.037), patients with long duration of AIRDs/nrAIDs (OR 1.01; 95%CI: 1.0-1.02, p = 0.016), those with comorbidities (OR: 2.8; 95%CI: 1.4-5.7, p = 0.005), and patients requiring oxygen supplementation for severe acute COVID-19 (OR: 3.8; 95%CI: 1.1-13.6, p = 0.039). Among patients with AIRDs, comorbidities (OR 2.0; 95%CI: 1.08-3.6, p = 0.026), and advanced treatment (OR: 1.9; 95%CI: 1.08-3.3, p = 0.024), or intensive care (OR: 3.8; 95%CI: 1.01-14.4, p = 0.047) for severe COVID-19 were risk factors for PCS. Notably, patients who developed PCS had poorer PROMIS global physical [15 (12-17) vs 12 (9-15)] and mental health [14 (11-16) vs 11 (8-14)] scores than those without PCS. Conclusion Individuals with AIRDs have a greater risk of PCS than HCs. Associated comorbid conditions, and advanced treatment or intensive care unit admission for severe COVID-19 confer a higher risk of PCS. It is imperative to identify risk factors for PCS for immediate multidisciplinary management in anticipation of poor physical and mental health. Disclosure L. Gupta: None. P. Sen: None. N. R: None. M. Joshi: None. S. Saha: None. K. Jagtap: None. V. Agarwal: None. O. Distler: Consultancies; Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. E. Nikiphorou: Honoraria; Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly. Grants/research support; Pfizer and Lilly. A. Tan: Honoraria; Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. S. Shinjo: None. N. Ziade: Honoraria; Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre. M. Milchert: None. I. Parodis: Honoraria; Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. M. Kuwana: None. A. Makol: None. J.D. Pauling: None. C. Wincup: None. J. Lilleker: Honoraria; Sanofi Genzyme, Roche, and Biogen. A. Nune: None. J. Day: Grants/research support; CSL Limited. H. Chinoy: Consultancies; Novartis, Eli Lilly, Orphazyme, Astra Zeneca. Honoraria; UCB, and Biogen. Grants/research support; Eli Lilly and UCB. V. Agarwal: None. R. Aggarwal: Consultancies; Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, and Roivant.
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
Naveen, R, Sen, Parikshit , Griger, Zoltán , Day, Jessica , Joshi, Mrudula , Nune, Arvind , Nikiphorou, Elena , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Jagtap, Kshitij , Parodis, Ioannis , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Lini, Daniele , Screiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Giollo, Alessandro, Alluno, Alessia, Ioannone, Florenzo, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos, Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A , Harifi, Ghita, Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Ravichandran, Naveen , Giollo, Alessandro , Schreiber, Karen , Gupta, Latika , Naveen, R , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Chen, Yi-Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Gutiérrez, Carlos Enrique Toro , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Milchert, Marcin , Joshi, Mrudula , Day, Jessica , Velikova, Tsvetelina , Parodis, Ioannis , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Nune, Arvind , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , Sen, Parikshit , Saha, Sreoshy , Griger, Zoltan , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Gracia‐Ramos, Abraham Edgar , Chen, Yi‐Ming , Makol, Ashima , Agarwal, Vishwesh , Barman, Bhupen , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Goo, Phonpen Akawatcharangura , Gheita, Tamer A. , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Andréoli, Laura , Ranjan, Rajiv , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Giollo, Alessandro, Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira , Kimura, Naoki, Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Giannini, Margherita , Maurier, F. , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Emorinken, Airenakho , Ugarte‐Gil, Manuel F. , Harifi, Ghita , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | April 21, 2023 | Volume: 63 | Issue: 1 | Pages: 127-139

10.1093/rheumatology/kead180 | PMID 37084267 Get It

Abstract Objectives Disease flares in the post–coronavirus disease 2019 (COVID-19) vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022, respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history and vaccination details. Flares of IIMs were defined as (a) patient self-reported, (b) immunosuppression (IS) denoted, (c) clinical sign directed and (d) with >7.9-point minimal clinically significant improvement difference worsening of Patient-Reported Outcomes Measurement Information System (PROMIS) PROMISPF10a score. Risk factors of flares were analysed using regression models. Results Of 15 165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians) and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7% and 19.6% patients by definitions (a) to (d), respectively, with a median time to flare of 71.5 (10.7–235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR 1.2; 95% CI 1.03, 1.6, P = 0.025) were prone to flares, while those receiving rituximab (OR 0.3; 95% CI 0.1, 0.7, P = 0.010) and AZA (OR 0.3, 95% CI 0.1, 0.8, P = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in IS. Asthma (OR 1.62; 95% CI 1.05, 2.50, P = 0.028) and higher pain visual analogue score (OR 1.19; 95% CI 1.11, 1.27, P < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion A diagnosis of IIMs confers an equal risk of flares in the post–COVID-19 vaccination period to AIRDs, with active disease, female gender and comorbidities conferring a higher risk. Disparity between patient- and physician-reported outcomes represents a future avenue for exploration.
Long‐term quality of life after treatment in sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Hwang, Peter H. , Fleseriu, Cara M. , Chan, Erik P., Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Suh, Jeffrey D. , Wang, Marilene B. , Sim, Myung‐Shin , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Chan, Erik, Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Lee, Jivianne K., Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 21, 2023 | Volume: 13 | Issue: 11 | Pages: 2030-2042

10.1002/alr.23171 | PMID 37082883 Get It

AbstractBackgroundQuality of life (QOL) for individuals with sinonasal malignancy (SNM) is significantly under‐studied, yet it is critical for counseling and may impact treatment. In this study we evaluated how patient, treatment, and disease factors impact sinonasal‐specific and generalized QOL using validated metrics in a large cohort over a 5‐year posttreatment time frame.MethodsPatients with SNM who underwent definitive treatment with curative intent were enrolled in a prospective, multisite, longitudinal observational study. QOL was assessed using the 22‐item Sino‐Nasal Outcome Test (SNOT‐22) and University of Washington Quality of Life Questionnaire (UWQOL) instruments at pretreatment baseline and multiple follow‐ups through 5 years posttreatment. Multivariable modeling was used to determine demographic, disease, and treatment factors associated with disease‐specific and generalized physical and social/emotional function QOL.ResultsOne hundred ninety‐four patients with SNM were analyzed. All QOL indices were impaired at pretreatment baseline and improved after treatment. SNOT‐22 scores improved 3 months and UWQOL scores improved 6 to 9 months posttreatment. Patients who underwent open compared with endoscopic tumor resection had worse generalized QOL (p < 0.001), adjusted for factors including T stage. Pterygopalatine fossa (PPF) involvement was associated with worse QOL (SNOT‐22, p < 0.001; UWQOL Physical dimension, p = 0.02). Adjuvant radiation was associated with worse disease‐specific QOL (p = 0.03). Neck dissection was associated with worse generalized physical function QOL (p = 0.01). Positive margins were associated with worse generalized social/emotional function QOL (p = 0.01).ConclusionDisease‐specific and generalized QOL is impaired at baseline in patients with SNM and improves after treatment. Endoscopic resection is associated with better QOL. PPF involvement, adjuvant radiation, neck dissection, and positive margins were associated with worse QOL posttreatment.
Economic Burden of Fatigue in Inflammatory Bowel Disease
Ananthakrishnan, Ashwin N. , Desai, Raj , Lee, Wan‐Ju , Griffith, Jenny, Chen, Naijun, Loftus, Edward V. , Ananthakrishnan, A N , Loftus, Edward V

Mayo Clinic

Crohn's & Colitis 360 | April 20, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad020 | PMID 37663925 Get It

AbstractBackgroundThis retrospective study gathered medical/pharmacy claims data on patients with inflammatory bowel disease (IBD) between January 01, 2000 and March 31, 2019 from the IBM MarketScan commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with IBD.MethodsEligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims), and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs were compared between cases and controls.ResultsMatched IBD cohorts (21 321 cases/21 321 controls) were identified (42% Crohn’s disease [CD] and 58% ulcerative colitis [UC]) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P &lt; .001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P &lt; .001); as well as significantly higher all-cause total direct healthcare costs (mean: $24 620 vs. $15 324; P &lt; .001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups.ConclusionsPresence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.
The Goal of Achieving High-Quality Surgical First-Line Therapy in Patients with Penile Cancer Is Important; However, Some Collective Efforts Are Still Required in Order to Reach It. Comment on Brassetti et al. Combined Reporting of Surgical Quality and Can
May, Matthias , Lebentrau, Steffen , Protzel, Chris, Chahoud, Jad , Pettaway, Curtis A. , Pagliaro, Lance C. , Watkin, Nick , Spiess, Philippe E. , Spiess, Philippe E , Ayres, Benjamin Edward , Albersen, Maarten , Brouwer, Oscar R. , Necchi, Andrea , Hakenberg, Oliver Walter

Mayo Clinic

Current Oncology | April 20, 2023 | Volume: 30 | Issue: 4 | Pages: 4269-4274

10.3390/curroncol30040325 | PMID 37185438 Get It

We read with great interest the manuscript by Brassetti et al. recently published in your journal and hope it will encourage discussion and debate around the optimization of the surgical management of patients with penile cancer (PECa) [...]